Truist raised the firm’s price target on NuVasive to $51 from $48 and keeps a Hold rating on the shares. Intra-quarter data points, including the firm’s Q2 hospital survey, increase confidence that procedure momentum will extend beyond Q2 into 2H23 with MedTech companies poised to deliver healthy beat and raises, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>